Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of extensive-stage small cell lung cancer (SCLC) * No mixed histology * Presence of ≥ 1 neuroendocrine marker (synaptophysin, chromogranin, or CD56) in tumor tissue * Achieved partial response (PR), complete response (CR), or stable disease (SD) ≤ 12 weeks of completing 4-6 courses of platinum-based chemotherapy regimen for extensive-stage SCLC * Patients with PR or SD must have measurable disease, defined as ≥ 1 lesion whose longest diameter can be accurately measured as ≥ 2.0 cm but \< 10 cm by chest x-ray OR as ≥ 1.0 cm but \< 10 cm by CT scan, CT component of a PET/CT scan, or MRI * If CT scan is used, it must be used for both pre- and post-treatment tumor assessments * Measurable disease is not required for patients with CR * Brain metastases allowed provided they have been stable for ≥ 4 weeks after completion of prior radiotherapy PATIENT CHARACTERISTICS: * ECOG performance status 0 or 1 * Life expectancy of ≥ 8 weeks * ANC ≥ 1,500/μL * Platelet count ≥ 100,000/μL * Hemoglobin ≥ 9 g/dL * Total bilirubin ≤ 1.5 times upper limit of normal (ULN) OR direct bilirubin normal * AST ≤ 3 times ULN (≤ 5 times ULN if liver has tumor involvement) * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use adequate contraception * Able to comply with study procedures to minimize virus exposure to others * Willing to provide required biologic specimens * Willing to return to NCCTG/CTSU enrolling institution for follow-up * Adequate lung function (i.e., not oxygen dependent) * The patient is eligible if not on a 24-hour oxygen schedule * No second primary malignancy within the past 5 years, except for the following: * Carcinoma in situ of the cervix * Non-melanomatous skin cancer * History of low-grade (Gleason score ≤ 6) localized prostate cancer (even if diagnosed \< 5 years prior to study entry) * Stage I breast cancer that was treated ≥ 5 years before study entry * Transitional cell carcinoma of the bladder (in situ) * No active hepatitis B or hepatitis C * No clinically significant infection * No significant traumatic injury within the past 4 weeks * No concurrent uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements PRIOR CONCURRENT THERAPY: * See Disease Characteristics * More than 4 weeks since prior radiotherapy (2 weeks for palliative radiotherapy to skeletal metastases) * Other prior radiation therapy (including WBRT, PCI, or Gamma Knife) is permitted as long as the following are true: * Recovered from prior radiotherapy (alopecia allowed) * No prior consolidation radiation therapy to the chest * No prior radiotherapy to \> 25% of bone marrow * For patients without brain metastases, WBRT or standard of care PCI completed ≥ 2 weeks before administration of NTX- 010/placebo * More than 365 days since prior immunotherapy or biologic therapy * More than 4 weeks since prior major surgery\* (i.e., laparotomy) or open biopsy * More than 2 weeks since prior minor surgery\* * No prior exposure to the Seneca Valley virus (NTX-010), as determined by negative serum antibodies * No concurrent combination antiretroviral therapy for HIV-positive patients NOTE: \*Insertion of a vascular access device is not considered major or minor surgery.